Sinovac Biotech’s late-stage trial of a potential vaccine in Bangladesh has become uncertain after Dhaka refused to meet the Chinese company’s demand for co-funding
By Ruma Paul DHAKA (Reuters) - India's Bharat Biotech has applied to conduct trials in Bangladesh for its coronavirus vaccine recently approved for em.
COVID-19 vaccine: Bharat Biotech seeks nod to conduct COVAXIN trials in Bangladesh
If allowed to go ahead, this would be the first trial of any coronavirus vaccine in Bangladesh and could give the densely-populated country of more than 160 million faster access to the shot for mass use
Reuters | January 21, 2021 | Updated 13:16 IST
The vaccine, developed with the Indian Council of Medical Research, was given the green light for restricted use in India this month without any efficacy data from a late-stage trial
India s Bharat Biotech has applied to conduct trials in Bangladesh for its coronavirus vaccine recently approved for emergency use at home, a senior official at Bangladesh s main medical research body told Reuters. If allowed to go ahead, this would be the first trial of any coronavirus vaccine in Bangladesh and could give the densely-populated country of more than 160 million faster access to the shot for mass use.
2 minutes read
Dhaka, Dec 20 (efe-epa) – The number of coronavirus cases in Bangladesh on Sunday crossed the 500,000-mark, authorities said, even as the densely populated South Asian country struggles to contain the pandemic.
The country recorded 1,153 new patients within the past 24 hours, taking the total number of cases to 500,713.
The death toll from the virus rose to 7,280 with 38 fresh cases reported since Saturday, according to a statement from the Directorate General of Health Services.
With these numbers, Bangladesh became the 27th country to have at least half-a-million cases of COVID-19, according to data complied by United States-based Johns Hopkins University.
Experts have warned that the real situation in the country of over 160 million people could be much worse than what the official figures indicated.